DnB Asset Management
ARQT icon

DnB Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

DnB Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$849K Buy
32,393
+6,992
+28% +$163K ﹤0.01% 661
2026
Q1 		$598K Sell
25,401
-2,385
-9% -$60.9K ﹤0.01% 720
2025
Q4 		$807K Buy
27,786
+802
+3% +$20.5K ﹤0.01% 652
2025
Q3 		$509K Sell
26,984
-1,187
-4% -$18.7K ﹤0.01% 672
2025
Q2 		$395K Buy
+28,171
New +$395K ﹤0.01% 659

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

DnB Asset Management's ARQT Position: Q2 2026 in Review

DnB Asset Management increased its Arcutis Biotherapeutics (ARQT) stake by 28% in Q2 2026, buying an estimated $163K and bringing the position to 32,393 shares worth $849K. The position accounts for ﹤0.01% of the portfolio, ranked #661.

DnB Asset Management first reported a position in ARQT in Q2 2025 and has held it in 5 quarters since. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • DnB Asset Management held 32,393 shares of Arcutis Biotherapeutics worth $849K as of Q2 2026.
  • DnB Asset Management bought 6,992 Arcutis Biotherapeutics shares in Q2 2026, an estimated $163K.
  • Arcutis Biotherapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #661 holding.
  • DnB Asset Management first reported a position in Arcutis Biotherapeutics in Q2 2025 and has held it in 5 quarters since.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.